Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.78
+0.01 (0.56%)
Market open: Aug 12, 2026, 2:05 PM EDT
1.77
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
| Name | Position |
|---|---|
| Dr. Imran Alibhai Ph.D. | CEO & Director |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D |
| Dr. John Kauh M.D. | Chief Medical Officer |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
| Mr. Dan Conn J.D., M.B.A. | CFO & Corporate Secretary |
| Mr. David J. Tweardy M.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Stephen O'Brien CPA | VP of Finance & Corporate Controller |
| Date | Type | Document |
|---|---|---|
| 2026-07-30 | 8-K | tm2621651d1_8k.htm |
| 2026-07-07 | 8-K | tm2619879d1_8k.htm |
| 2026-06-11 | 8-K | tm2617528d1_8k.htm |
| 2026-05-08 | POS AM | tm269412-2_posam.htm |
| 2026-05-08 | CORRESP | filename1.htm |
| 2026-05-08 | 8-K | tm2613977d1_8k.htm |
| 2026-05-08 | 10-Q | tvrd-20260331x10q.htm |
| 2026-05-01 | S-3 | tm2613101-1_s3.htm |
| 2026-04-23 | DEFA14A | tm266756d2_defa14a.htm |
| 2026-04-23 | ARS | tm266752d2_ars.pdf |